Home › Myotonic Dystrophy
Myotonic Dystrophy clinical trials recruiting in the U.S.
19 studies for Myotonic Dystrophy are recruiting participants at sites across the United States.
Cities with the most studies
- Richmond, VA8 studies
- Rochester, NY7 studies
- Boston, MA4 studies
- Los Angeles, CA4 studies
- Cedar Rapids, IA3 studies
- Gainesville, FL3 studies
By state
- California5 studies
- Florida3 studies
- Iowa3 studies
- Kansas4 studies
- Massachusetts4 studies
- New York8 studies
- North Carolina4 studies
- Pennsylvania3 studies
- Texas3 studies
- Virginia8 studies
Recently updated studies
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
RecruitingPhase 3
Ages 16 and older · All sexes · Updated Sep 25, 2026 · NCT07486934A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1
RecruitingPhase 1/2
Ages 10 to 55 · All sexes · Updated Sep 21, 2026 · NCT06844214Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension
RecruitingObservational study
Ages 18 to 70 · All sexes · Updated Sep 4, 2026 · NCT07700225Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
RecruitingObservational study
Ages 3 to 17 · All sexes · Updated Aug 11, 2026 · NCT06747884DMCRN-02-001: Assessing Pediatric Endpoints in DM1
RecruitingObservational study
59 Months · All sexes · Updated Jun 10, 2026 · NCT05224778Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
RecruitingObservational study
Ages 18 to 70 · All sexes · Updated Jun 10, 2026 · NCT03981575Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy
RecruitingObservational study
Ages 0 to 17 · All sexes · Updated Jun 5, 2026 · NCT07630389Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
RecruitingPhase 3
Ages 4 to 18 · Men · Updated May 27, 2026 · NCT07608432Investigating Exercise in Myotonic Dystrophy Type 2 (DM2)
Recruiting
Ages 18 to 70 · All sexes · Updated Apr 15, 2026 · NCT06716931Remote Assessments and Genetic Determinants of Myotonic Dystrophy
RecruitingObservational study
Ages 18 to 88 · All sexes · Updated Apr 1, 2026 · NCT07505342Study of ATX-01 in Participants With DM1
RecruitingPhase 1/2
Ages 18 to 64 · All sexes · Updated Feb 10, 2026 · NCT06300307Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 65 · All sexes · Updated Jan 23, 2026 · NCT07362875Biomarker Development for Muscular Dystrophies
RecruitingObservational studyHealthy volunteers welcome
Ages 5 and older · All sexes · Updated Nov 24, 2025 · NCT05019625Extracellular RNA Biomarkers of Myotonic Dystrophy
RecruitingObservational studyHealthy volunteers welcome
Ages 5 and older · All sexes · Updated Nov 24, 2025 · NCT05020002Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 24, 2025 · NCT06075693Long-Term Development of Muscular Dystrophy Outcome Assessments
RecruitingObservational study
Ages 6 to 50 · All sexes · Updated Nov 18, 2025 · NCT05989620Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
RecruitingObservational studyHealthy volunteers welcome
All ages · All sexes · Updated Oct 15, 2025 · NCT00082108Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
RecruitingPhase 2/3
Ages 6 to 45 · All sexes · Updated May 28, 2025 · NCT05004129Myotonic Dystrophy Family Registry
RecruitingObservational study
All ages · All sexes · Updated Nov 21, 2024 · NCT02398786From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.